JP7335957B2 - 抗体-alk5阻害剤コンジュゲートおよびその使用 - Google Patents

抗体-alk5阻害剤コンジュゲートおよびその使用 Download PDF

Info

Publication number
JP7335957B2
JP7335957B2 JP2021523548A JP2021523548A JP7335957B2 JP 7335957 B2 JP7335957 B2 JP 7335957B2 JP 2021523548 A JP2021523548 A JP 2021523548A JP 2021523548 A JP2021523548 A JP 2021523548A JP 7335957 B2 JP7335957 B2 JP 7335957B2
Authority
JP
Japan
Prior art keywords
adc
antibody
linker
antigen
alk5 inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500486A (ja
Inventor
エー. トーマス-カーヤット,ドリー
Original Assignee
シンシス セラピューティクス,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンシス セラピューティクス,インコーポレイテッド filed Critical シンシス セラピューティクス,インコーポレイテッド
Publication of JP2022500486A publication Critical patent/JP2022500486A/ja
Priority to JP2023080821A priority Critical patent/JP7573685B2/ja
Application granted granted Critical
Publication of JP7335957B2 publication Critical patent/JP7335957B2/ja
Priority to JP2024180002A priority patent/JP7798998B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021523548A 2018-07-09 2018-07-09 抗体-alk5阻害剤コンジュゲートおよびその使用 Active JP7335957B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023080821A JP7573685B2 (ja) 2018-07-09 2023-05-16 抗体-alk5阻害剤コンジュゲートおよびその使用
JP2024180002A JP7798998B2 (ja) 2018-07-09 2024-10-15 抗体-alk5阻害剤コンジュゲートおよびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/041291 WO2020013803A1 (en) 2018-07-09 2018-07-09 Antibody-alk5 inhibitor conjugates and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023080821A Division JP7573685B2 (ja) 2018-07-09 2023-05-16 抗体-alk5阻害剤コンジュゲートおよびその使用

Publications (2)

Publication Number Publication Date
JP2022500486A JP2022500486A (ja) 2022-01-04
JP7335957B2 true JP7335957B2 (ja) 2023-08-30

Family

ID=69142765

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021523548A Active JP7335957B2 (ja) 2018-07-09 2018-07-09 抗体-alk5阻害剤コンジュゲートおよびその使用
JP2023080821A Active JP7573685B2 (ja) 2018-07-09 2023-05-16 抗体-alk5阻害剤コンジュゲートおよびその使用
JP2024180002A Active JP7798998B2 (ja) 2018-07-09 2024-10-15 抗体-alk5阻害剤コンジュゲートおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023080821A Active JP7573685B2 (ja) 2018-07-09 2023-05-16 抗体-alk5阻害剤コンジュゲートおよびその使用
JP2024180002A Active JP7798998B2 (ja) 2018-07-09 2024-10-15 抗体-alk5阻害剤コンジュゲートおよびその使用

Country Status (7)

Country Link
US (1) US20210299268A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820467A4 (cg-RX-API-DMAC7.html)
JP (3) JP7335957B2 (cg-RX-API-DMAC7.html)
CN (2) CN119488607A (cg-RX-API-DMAC7.html)
AU (2) AU2018431586B2 (cg-RX-API-DMAC7.html)
CA (1) CA3104934A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020013803A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023113685A (ja) * 2018-07-09 2023-08-16 シンシス セラピューティクス,インコーポレイテッド 抗体-alk5阻害剤コンジュゲートおよびその使用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
WO2020256721A1 (en) * 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
CN115052663B (zh) * 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
JP7842690B2 (ja) 2020-02-19 2026-04-08 ナミ セラピューティクス, インコーポレイテッド がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
US12668593B2 (en) 2020-09-28 2026-06-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Pyrazole compound and preparation method therefor and use thereof
WO2022076905A1 (en) * 2020-10-09 2022-04-14 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
CN115192731B (zh) * 2021-04-12 2023-09-26 中国科学院上海有机化学研究所 一种抗体药物偶联物的制备方法
AU2023230346A1 (en) * 2022-03-09 2024-10-17 Orum Therapeutics, Inc. Activators of effector t cells
WO2024258967A1 (en) * 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502164A (ja) 2002-09-06 2006-01-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド イミダゾロピリジンならびにその生成および使用方法
JP2007514652A (ja) 2003-11-06 2007-06-07 シアトル ジェネティックス, インコーポレイテッド リガンドに結合体化可能なモノメチルバリン化合物
JP2009519977A (ja) 2005-12-16 2009-05-21 アルコン,インコーポレイテッド Alk5調整剤を用いた眼内圧のコントロール
WO2016115218A1 (en) 2015-01-14 2016-07-21 The California Institute For Biomedical Research Antibody drug conjugates for the treatment of immune conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
EP1539748A1 (en) * 2002-07-31 2005-06-15 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
AU2009270988A1 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US8871744B2 (en) * 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
US10131682B2 (en) * 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
SG11201705721WA (en) * 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
US20170158772A1 (en) * 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
AU2018266103B2 (en) * 2017-05-09 2024-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
US20210154188A1 (en) * 2018-04-02 2021-05-27 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
AU2018431586B2 (en) 2018-07-09 2025-03-20 Synthis Therapeutics, Inc Antibody-ALK5 inhibitor conjugates and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502164A (ja) 2002-09-06 2006-01-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド イミダゾロピリジンならびにその生成および使用方法
JP2007514652A (ja) 2003-11-06 2007-06-07 シアトル ジェネティックス, インコーポレイテッド リガンドに結合体化可能なモノメチルバリン化合物
JP2009519977A (ja) 2005-12-16 2009-05-21 アルコン,インコーポレイテッド Alk5調整剤を用いた眼内圧のコントロール
WO2016115218A1 (en) 2015-01-14 2016-07-21 The California Institute For Biomedical Research Antibody drug conjugates for the treatment of immune conditions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023113685A (ja) * 2018-07-09 2023-08-16 シンシス セラピューティクス,インコーポレイテッド 抗体-alk5阻害剤コンジュゲートおよびその使用
JP7573685B2 (ja) 2018-07-09 2024-10-25 シンシス セラピューティクス,インコーポレイテッド 抗体-alk5阻害剤コンジュゲートおよびその使用

Also Published As

Publication number Publication date
JP2022500486A (ja) 2022-01-04
JP2025023920A (ja) 2025-02-19
WO2020013803A1 (en) 2020-01-16
AU2018431586A1 (en) 2021-01-21
AU2025204026A1 (en) 2025-06-19
CN119488607A (zh) 2025-02-21
AU2018431586B2 (en) 2025-03-20
CN112601522B (zh) 2024-11-05
JP7573685B2 (ja) 2024-10-25
CN112601522A (zh) 2021-04-02
US20210299268A1 (en) 2021-09-30
EP3820467A1 (en) 2021-05-19
EP3820467A4 (en) 2022-05-04
JP2023113685A (ja) 2023-08-16
JP7798998B2 (ja) 2026-01-14
CA3104934A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
JP7798998B2 (ja) 抗体-alk5阻害剤コンジュゲートおよびその使用
US11987558B1 (en) ALK5 inhibitors and their uses
JP7854462B2 (ja) 抗体-alk5阻害剤コンジュゲートおよびその使用
JP2018502839A (ja) Bcl−xL阻害性化合物およびこれを含む抗体薬物コンジュゲート
JP2018506509A (ja) 細胞透過性Bcl−xL阻害剤との抗体薬物コンジュゲート
JP2026000988A (ja) Alk5阻害剤複合体およびその使用
JP2024506300A (ja) 免疫刺激化合物及びコンジュゲート体
CN112739341A (zh) 抗cd2抗体药物缀合物(adc)在同种异体细胞疗法中的用途
JP2025525904A (ja) 免疫刺激性抗pd-l1-薬物コンジュゲート
KR20250004951A (ko) 효과기 t세포의 활성화제
WO2024258967A1 (en) Anti-cd5 antibodies and their uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230516

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230725

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230818

R150 Certificate of patent or registration of utility model

Ref document number: 7335957

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150